Trial · NCT00448123
The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
NCT00448123, Not applicable, Completed, Robert Swor; results first posted 2016-10-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients. Trials, record NCT00448123. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00448123
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients
- NCT number
- NCT00448123
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 127 participants, actual
- Lead sponsor
- Robert Swor
- Conditions
- Kidney Stones, Ureteral Stones
- Interventions
- Tamsulosin, Placebo
- First posted
- 2007-03-15
- Last updated
- 2016-10-12
- Results first posted
- 2016-10-12
- Limitations and caveats
- Limitations of this study include non-consecutive enrollment and small sample size.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Stone Passage | 1-7 days | Participants were asked during the follow-up phone call to indicate if their stone had passed within seven days. Phone calls were conducted at days 1, 2, 3, 7, 10 and 30 days after the emergency department discharge. Data is reported based on the information obtained up to the 7th day. |
| Secondary | Amount (Mean Number of Tablets Taken) of Pain Medication Taken by Subjects up to Seven (7) Days Post Emergency Department Discharge | 1-7 days | |
| Secondary | High Pain Score by Treatment Group | 7 Days | Severity of Patient Pain at 7 days Post Emergency Department Visit. Patients were asked to describe their pain severity at each followup phone call, using a numerical scale, ranging from 0 (no pain) to 10 (worst possible pain). We report this measure at 7 days. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Stone Passage | 1-7 days | In the placebo group, of the 47 subjects 18 (46.2%) passed their stone by Day 7. In the Tamsulosin group, of the 53 subjects 21 (53.9%) passed their stone by Day 7. | participants | NUMBER |
| SECONDARY | Amount (Mean Number of Tablets Taken) of Pain Medication Taken by Subjects up to Seven (7) Days Post Emergency Department Discharge | 1-7 days | The data table is limited to the information collected at Day 7. Of the 53 subjects in the placebo group only 29 provided information regarding pain medication at the Day 7 interview. For the Tamsulosin group, only 15 out of 47 provided the pain medication information at the Day 7 interview. At Day 7 each group had only 3 non-zero responses. | Pain tablets | MEAN |
| SECONDARY | High Pain Score by Treatment Group | 7 Days | The data table is limited to the information collected at Day 7. Of the 53 subjects in the placebo group only 29 provided information at the Day 7 interview. For the Tamsulosin group, only 15 out of 47 provided information at the Day 7 interview. | units on a scale | MEAN |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Stone Passage | Placebo | 18 | participants | ||
| Stone Passage | Tamsulosin | 21 | participants | ||
| Amount (Mean Number of Tablets Taken) of Pain Medication Taken by Subjects up to Seven (7) Days Post Emergency Department Discharge | Placebo | 0.4 | Full Range 0 to 4 | Pain tablets | |
| Amount (Mean Number of Tablets Taken) of Pain Medication Taken by Subjects up to Seven (7) Days Post Emergency Department Discharge | Tamsulosin | 0.6 | Full Range 0 to 6 | Pain tablets | |
| High Pain Score by Treatment Group | Placebo | 1.69 | Full Range 0 to 7 | units on a scale | |
| High Pain Score by Treatment Group | Tamsulosin | 2.4 | Full Range 0 to 8 | units on a scale |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Placebo | 62 | |
| Overall Study | STARTED | Tamsulosin | 65 | |
| Overall Study | COMPLETED | Placebo | 47 | |
| Overall Study | COMPLETED | Tamsulosin | 53 | |
| Overall Study | NOT COMPLETED | Placebo | 15 | |
| Overall Study | NOT COMPLETED | Tamsulosin | 12 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Dizziness | Nervous system disorders | Placebo | 5 | 47 | |
| other | Dizziness | Nervous system disorders | Tamsulosin | 4 | 53 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Placebo | ||
| Total, all-cause mortality | Tamsulosin | ||
| Total, other adverse events | Placebo | 5 | 47 |
| Total, other adverse events | Tamsulosin | 4 | 53 |
| Total, serious adverse events | Placebo | 0 | 47 |
| Total, serious adverse events | Tamsulosin | 0 | 53 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 26429522 | RESULT |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons2
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Tamsulosin vs Placebo: Stone Passage | Trial comparisons |
| Tamsulosin vs Placebo: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT00448123
GET https://conductscience.org/api/trials/v1/NCT00448123/registered